Introduction: Several studies have implicated the PIK3/AKT pathway in the pathophysiology of cancer progression as its activation seems to be aberrant in several forms of cancer. The purpose of the present systematic review is to evaluate the impact of PIK3CA mutations on survival outcomes of patients with cervical cancer. Methods: We used the Medline (1966–2020), Scopus (2004–2020), ClinicalTrials.gov (2008–2020), EMBASE (1980–2020), Cochrane Central Register of Controlled Trials (CENTRAL) (1999–2020), and Google Scholar (2004–2020) databases in our primary search along with the reference lists of electronically retrieved full-text papers. Statistical meta-analysis was performed with the RevMan 5.3 software. Results: Overall, 12 articles were included in the present study that comprised 2,196 women with cervical cancer. Of those, 3 studies did not report significant differences in survival outcomes among patients with mutated versus wild-type PIK3CA tumors, 5 studies reported decreased survival outcomes, and 3 studies revealed increased survival rates. The meta-analysis revealed that patients with the mutated PIK3CA genotypes had worse overall survival compared to patients with wild-type PIK3CA (HR 2.31; 95% CI: 1.51, 3.55; 95% PI: 0.54, 9.96; data from 3 studies) and the same was observed in the case of DFS rates (HR 1.82; 95% CI: 1.47, 2.25; 95% PI: 1.29, 2.56; data from 4 studies). Conclusion: Current evidence concerning the impact of PIK3CA mutations on survival outcomes of patients with cervical cancer is inconclusive, although the majority of included studies support a potential negative effect, primarily among those with squamous cell carcinoma tumors.
Acta Cytologica

中文翻译：

---

PIK3CA突变及其对宫颈癌患者生存结局的影响：系统评价。

简介：一些研究已将PIK3 / AKT途径牵涉到癌症进展的病理生理中，因为PIK3 / AKT途径的激活似乎在多种形式的癌症中都是异常的。本系统综述的目的是评估PIK3CA突变对宫颈癌患者生存结果的影响。方法：我们使用Medline（1966-2020），Scopus（2004-2020），ClinicalTrials.gov（2008-2020），EMBASE（1980-2020），Cochrane对照试验中央注册系统（CENTRAL）（1999-2020），以及我们主要搜索中的Google Scholar（2004–2020）数据库以及电子检索全文论文的参考列表。使用RevMan 5.3软件进行统计荟萃分析。结果：总体而言，本研究包括12篇文章，包括2196名宫颈癌女性。在这些研究中，有3项研究未报告突变型和野生型PIK3CA肿瘤患者的生存结局有显着差异； 5项研究报告了生存结局降低，而3项研究表明生存率提高。荟萃分析显示，与野生型PIK3CA患者相比，具有突变型PIK3CA基因型的患者总体生存率较差（HR 2.31； 95％CI：1.51、3.55； 95％PI：0.54、9.96；来自3个研究的数据）和在DFS发生率方面也观察到了相同的结果（HR 1.82； 95％CI：1.47，2.25； 95％PI：1.29，2.56； 4个研究的数据）。结论：尽管有关纳入的大多数研究都支持潜在的负面影响，但主要针对鳞状细胞癌患者，目前有关PIK3CA突变对宫颈癌患者生存结果影响的证据尚无定论。
细胞学学报